{"id":"NCT01352793","sponsor":"Pfizer","briefTitle":"A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","officialTitle":"A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2011-05-12","resultsPosted":"2015-03-11","lastUpdate":"2015-03-11"},"enrollment":5715,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"rLP2086 vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"control","otherNames":[]}],"arms":[{"label":"rLP2086 vaccine","type":"EXPERIMENTAL"},{"label":"control","type":"OTHER"}],"summary":"A multicenter phase 3 safety trial in which 5,700 subjects will be assigned in a 2:1 ratio to receive 120 Î¼g rLP2086 vaccine in a 0, 2, 6 month schedule or control. The control group will receive HAVRIX vaccine at month 0 and 6 and saline at month 2.\n\nAll subjects will be followed for 6 months after the last vaccination to assess safety and tolerability.","primaryOutcome":{"measure":"Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study","timeFrame":"Vaccination 1 up to 6 months after Vaccination 3","effectByArm":[{"arm":"Group 1: rLP2086","deltaMin":1.55,"sd":null},{"arm":"Group 2: HAV/Saline/HAV","deltaMin":2.52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":86,"countries":["United States","Australia","Chile","Czechia","Denmark","Estonia","Finland","Germany","Lithuania","Poland","Spain","Sweden"]},"refs":{"pmids":["35164991"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971014&StudyName=A%20Global%20Phase%203%20Safety%20Study%20of%20120%20mcg%20rLP2086%20Vaccine%20in%20Adolescents%20and%20Young%20Adults%20Aged%2010%20to%2025%20Years"]},"adverseEventsSummary":{"seriousAny":{"events":59,"n":3796},"commonTop":["Injection site pain","Headache","Pyrexia","Upper respiratory tract infection","Nasopharyngitis"]}}